CMBA
ANIK icon

C.M. Bidwell & Associates’s Anika Therapeutics ANIK Stock Holding History

C.M. Bidwell & Associates’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,165
Closed -$164K – 354
2019
Q4 		$164K Sell
3,165
-195
-6% -$11.3K 0.15% 128
2019
Q3 		$184K Buy
3,360
+2,275
+210% +$117K 0.18% 137
2019
Q2 		$44K Buy
+1,085
New +$39.6K 0.04% 251

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Boston Trust Walden
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

C.M. Bidwell & Associates's ANIK Position: Q1 2020 in Review

C.M. Bidwell & Associates sold out of Anika Therapeutics (ANIK) in Q1 2020, closing a stake of 3,165 shares — an estimated $164K sold.

C.M. Bidwell & Associates first reported a position in ANIK in Q2 2019 and held it in 3 quarters. The position peaked at $184K in Q3 2019. 163 funds tracked by Wall St. Rank hold ANIK as of Q1 2020.

  • C.M. Bidwell & Associates reported no remaining Anika Therapeutics position as of Q1 2020 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 3,165 Anika Therapeutics shares in Q1 2020, an estimated $164K.
  • C.M. Bidwell & Associates first reported a position in Anika Therapeutics in Q2 2019 and held it in 3 quarters.
  • C.M. Bidwell & Associates's Anika Therapeutics position peaked at $184K in Q3 2019.
  • 163 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2020.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2020, filed 15 May 2020.